Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,543 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07395479RecruitingEarly Phase 1
CAR-T therapy study for advanced blood and solid cancers
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07389239RecruitingPhase 1/Phase 2
Immunotherapy for ovarian cancer and other advanced tumors
This study tests an immunotherapy treatment for people with advanced solid tumors, including ovarian cancer, sarcoma, prostate, breast, lung, and others. It is designed for tumors that show a specific marker called NY-ESO-1, and aims to see if the treatment can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT06484816RecruitingPhase 1
TGRX-1942 study for advanced solid tumor or blood cancer
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hangzhou, ZhejiangAges 18 years+ - NCT07378436RecruitingEarly Phase 1
Testing a new drug for cancer-related belly fluid
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
BeijingAges 18–75 - NCT07378969Recruiting
Study on T-cell cancers after tisagenlecleucel treatment
This study looks at people who developed a new T-cell cancer after receiving the CAR-T therapy tisagenlecleucel (Kymriah). Researchers want to understand these rare cancers by testing stored tumor samples. You may be eligible if you had tisagenlecleucel and were later diagnosed with a T-cell malignancy.
Kurume, FukuokaAges 15–15 - NCT04016675Recruiting
Radiation before surgery for cancer of the tear sac
This trial studies giving radiation before surgery for malignant (cancerous) tumors of the tear sac. It may help shrink the tumor and improve how well treatment works when surgery is planned.
ShanghaiAges 18–80 - NCT07368803RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for bile duct cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) made from your tumor's unique markers to help prevent cancer from coming back after surgery for bile duct or other digestive cancers. It may be an option if standard treatments have stopped working or caused side effects.
Hangzhou, ZhejiangAges 18–75 - NCT07368127RecruitingPhase 1
Study of TPD3310 for advanced solid tumors
This trial tests an experimental drug called TPD3310 for people with advanced solid tumors (like lung, stomach, liver, or other cancers) that have worsened after standard treatments or cannot tolerate them. It aims to see if the drug is safe and works, especially for tumors with a specific marker called c-MET.
Beijing, Beijing MunicipalityAges 18–75 - NCT07368478RecruitingPhase 1
Study of BC2027 for advanced solid tumors with GPC3
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Nanchang, JiangxiAges 18–70 - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Basking Ridge, New JerseyAges 18 years+ - NCT06851702Recruiting
Tracking hormone side effects from immunotherapy in blood cancer
This study looks at people with certain types of blood cancer (lymphoma or leukemia) who are getting immunotherapy drugs called checkpoint inhibitors. Researchers want to learn how these drugs affect the body's hormone system, so doctors can better manage these side effects.
Bologna, BolognaAges 18 years+ - NCT05868876RecruitingPhase 1
Testing AK127 plus AK104 for advanced cancers
This Phase 1 study tests the safety and early anti-cancer activity of AK127 given together with AK104 in people with advanced solid tumors. You may be considered if standard treatments have already been tried or aren’t suitable for you.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07349849RecruitingEarly Phase 1
mRNA Drug Targeting CD19 for Blood Cancers
This study tests a new mRNA-based medicine that targets CD19 on cancer cells. It is for people with B-cell lymphoma or leukemia who have run out of standard treatment options.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07340190RecruitingPhase 1
How pelabresib affects other drugs in advanced cancer
This study tests how a new drug (pelabresib) interacts with other medicines like diabetes pills, a sedative, and birth control pills. It is for people with advanced cancer to help understand safe dosing.
BordeauxAges 18 years+ - NCT07338604RecruitingEarly Phase 1
UTAA07 cell therapy for relapsed CD7+ blood cancers
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
Suzhou, JiangsuAges 18 years+ - NCT07338838RecruitingPhase 1
Testing TQB3142 in advanced tumors
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
Guangzhou, GuangdongAges 18–75 - NCT07339085Recruiting
Advanced MRI for brain tumor recurrence or radiation damage
This study uses advanced MRI scans to better tell the difference between a returning brain tumor and radiation injury. It may help guide your treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT07332858RecruitingPhase 1/Phase 2
Study of an experimental drug for lung cancer with fluid in the chest
This trial tests a new drug given directly into the chest cavity to treat fluid buildup caused by non-small cell lung cancer. It may help ease breathing problems and control the fluid.
Beijing, Beijing MunicipalityAges 18–75 - NCT06548958Recruiting
TBI and chemotherapy before a second stem cell transplant
This trial tests a combination of total body irradiation and two chemotherapy drugs as preparation for a second stem cell transplant in people with blood cancers that relapsed or didn't respond to the first transplant.
Suzhou, JiangsuAges 14–70 - NCT07309900RecruitingPhase 1
Testing IASO208 for relapsed or hard-to-treat B-cell cancers
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
Wuhan, HubeiAges 18–75 - NCT07299747RecruitingPhase 1/Phase 2
Study of VBC103 for advanced solid tumors
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07301801RecruitingEarly Phase 1
New scan for detecting and staging certain cancers
This trial tests a new imaging agent (68Ga-FL-031) to see if it can help find and stage tumors in people with small cell lung cancer, breast cancer, nasopharyngeal cancer, or other cancers. The goal is to improve diagnosis and treatment planning.
Wuhan, HubeiAges 18 years+ - NCT05475600Recruiting
Biofeedback and relaxation for ICU patients with blood cancers
This trial tests whether guided biofeedback and relaxation techniques can help people with blood cancers while they are in the ICU. It may improve comfort and stress during critical illness, compared with standard care.
MetzAges 18–75
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,543 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.